We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A10522
CAS No.
191732-72-6
Formula
C13H13N3O3
Mol. Weight
259.3

Documents & Downloads

Lenalidomide (CC-5013)

Ubiquitin ligase inducer

Lenalidomide is a derivative of thalidomide. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the micro environment support for tumor cells, and immunomodulatory role. It induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.

In Stock

Publications for Lenalidomide

6 publications citing this product

  1. Kazuya Ishiguro, .et al. , Cancer Lett, 2025, Oct 28:631:217941 PMID: 40701319
  2. Sumie Fujii, .et al. , Stem Cells and Development, 2025, 34: 9-10 PMID: 40130551
  3. Daniel A. Rauch, .et al. , Retrovirology, 2020, 17: 27 PMID: 32859220
  4. A Hayano, .et al. , Int J Clin Oncol, 2019, 1-10 PMID: 30993483
  5. Kumar R, .et al. , Mol Biol Rep, 2018, Oct 11 PMID: 30311125
  6. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Cereblon  

Cellular Effect

Cell Line Activity Value Description Reference
EC9706 IC50 340.3 μg/mL Antiproliferative activity against human EC9706 cells after 48 hrs by CCK-8 assay [PMID: 28757066]
HCC827 IC50 > 10 μM Antiproliferative activity against human HCC827 cells harboring EGFRDel19 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 31951960]
HEK293 IC50 5.19 μM Inhibition of BRD4 bromodomain 2 (unknown origin) in HEK293 cells cotransfected with eGFP by flow cytometry based mCherry reporter gene analysis [PMID: 32550984]
JeKo-1 IC50 > 20000 nM Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
JeKo-1 IC50 > 20000 nM Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
JeKo-1 IC50 > 20000 nM Antiproliferative activity against human JeKo1 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay [PMID: 31125896]
K562 IC50 > 10 μM Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay [PMID: 36306539]
K562 IC50 > 10 μM Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay [PMID: 34217059]
Kasumi 1 IC50 > 20000 nM Antiproliferative activity against human Kasumi-1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay [PMID: 31125896]
MCF-10A IC50 > 20 μM Cytotoxicity against human MCF10A cells after 72 hrs by MTS assay [PMID: 29795767]
MM1.S IC50 > 20000 nM Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay [PMID: 35635954]
MM1.S IC50 0.081 μM Antiproliferative activity against human MM1.S cells assessed as reduction in cell growth measured after 7 days culturing by CellTiter 96 Aqueous non-radioactive cell proliferation assay [PMID: 33328101]
MM1.S IC50 50 nM Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay [PMID: 31125896]
MM1.S IC50 70.17 nM Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay [PMID: 35635954]
MV4-11 IC50 > 20000 nM Antiproliferative activity against human MV411 cells after 72 hrs by MTS assay [PMID: 29795767]
MV4-11 IC50 > 20000 nM Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay [PMID: 31125896]
NAMALVA IC50 0.36 μM Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting [PMID: 23168019]
PBMC IC50 > 20000 nM Cytotoxicity against human PBMC cells by CellTiter96 Aqueous non-radioactive cell proliferation assay [PMID: 31125896]
PBMC IC50 0.1 μM Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA [PMID: 23168019]

19 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 191732-72-6
Applications Ubiquitin ligase inducer
Formula C13H13N3O3
Molecular Weight 259.3
Synonyms Revlimid; CC-5013
SMILES
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 46 mg/mL (177.43 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+40%PEG 300+5%Tween80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Publications

6 publications citing this product

  1. Kazuya Ishiguro, .et al. , Cancer Lett, 2025, Oct 28:631:217941 PMID: 40701319
  2. Sumie Fujii, .et al. , Stem Cells and Development, 2025, 34: 9-10 PMID: 40130551
  3. Daniel A. Rauch, .et al. , Retrovirology, 2020, 17: 27 PMID: 32859220
  4. A Hayano, .et al. , Int J Clin Oncol, 2019, 1-10 PMID: 30993483
  5. Kumar R, .et al. , Mol Biol Rep, 2018, Oct 11 PMID: 30311125
  6. Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168

Added to your cart

View Cart Checkout
Loading...